-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Nurix Therapeutics, Maintains $26 Price Target

Benzinga·12/08/2025 12:15:19
語音播報
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $26 price target.